A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: Implications for physiological brain imaging of patients with intracranial tumors

Neurosurgery

Volumn 67, Issue 6, 2010, Pages 1799-1815

  Kotsarini, Christina ^a   Griffiths, Paul D ^a   Wilkinson, Iain D ^a   Hoggard, Nigel ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Blood brain barrier; Dexamethasone; Glioma; Magnetic resonance imaging; Perfusion; Steroid

Indexed keywords

DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18;

BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN PERFUSION; BRAIN TISSUE; CANCER SURVIVOR; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DATA BASE; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG MECHANISM; EMBASE; HUMAN; IN VIVO STUDY; INTRACRANIAL TUMOR; MEDLINE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PERFUSION WEIGHTED IMAGING; PERMEABILITY BARRIER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN; BRAIN EDEMA; BRAIN NEOPLASMS; DEXAMETHASONE; DIAGNOSTIC IMAGING; HUMANS; MEDLINE;

EID: 78650516878     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3181fa775b     Document Type: Review

References (171)

1. McClelland S 3rd, Long DM. Genesis of the use of corticosteroids in the treatment and prevention of brain edema. Neurosurgery. 2008;62(4):965-967; discussion 967-968.
2. Galicich JH, French LA. Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat. 1961;12:169-174.
3. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet. 1961;81:46-53.
4. Sarin R, Murthy V. Medical decompressive therapy for primary and metastatic intracranial tumours. Lancet Neurol. 2003;2(6):357-365.
5. Stummer W. Mechanisms of tumor-related brain edema. Neurosurg Focus. 2007;22(5):E8.
6. Nahaczewski AE, Fowler SB, Hariharan S. Dexamethasone therapy in patients with brain tumors-a focus on tapering. J Neurosci Nurs. 2004;36(6):340-343.
7. Alberti E, Hartmann A, Schutz HJ, Schreckenberger F. The effect of large doses of dexamethasone on the cerebrospinal fluid pressure in patients with supratentorial tumors. J Neurol. 1978;217(3):173-181.
8. Marmarou A, Signoretti S, Fatouros PP, Portella G, Aygok GA, Bullock MR. Predominance of cellular edema in traumatic brain swelling in patients with severe head injuries. J Neurosurg. 2006;104(5):720-730.
9. Raslan A, Bhardwaj A. Medical management of cerebral edema. Neurosurg Focus. 2007;22(5):E12.
10. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68(6):835-853.
11. Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16(9):1041-1048.
12. Akella NS, Twieg DB, Mikkelsen T, et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging. 2004;20(6):913-922.
13. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist. 1999;4(3):209-224.
14. Korfel A, Thiel E. Targeted therapy and blood-brain barrier. Recent results. Cancer Res. 2007;176:123-133.
15. Bell BA. Measurement of changes in brain water in man by magnetic resonance imaging. Ann R Coll Surg Engl. 1989;71(6):375-380.
16. Bell BA, Smith MA, Kean DM, et al. Brain water measured by magnetic resonance imaging. Correlation with direct estimation and changes after mannitol and dexamethasone. Lancet. 1987;1(8524):66-69.
17. Col LTaSKJ. Cerebral edema and its management. MJAFI. 2003;59(4):326-331.
18. Liang D, Bhatta S, Gerzanich V, Simard JM. Cytotoxic edema: mechanisms of pathological cell swelling. Neurosurg Focus. 2007;22(5):E2.
19. Rosenberg GA. Ischemic brain edema. Prog Cardiovasc Dis. 1999;42(3):209-216.
20. Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. Neurosurg Focus. 2007;22(5):E1.
21. Milhorat TH. Classification of the cerebral edemas with reference to hydrocephalus and pseudotumor cerebri. Childs Nerv Syst. 1992;8(6):301-306.
22. Senger DR, Van deWater L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12(3-4):303-324.
23. Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke. 2002;33(2):497-501.
24. Whittle IR, Piper IR, Miller JD. The contribution of arachidonic acid to the aetiology and pathophysiology of focal brain oedema; studies using an infusion oedema model. Acta Neurochir (Wien). 1991;113(1-2):57-68.
25. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA. Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry. 2002;72(2):262-265.
26. Ohata K, Marmarou A. Clearance of brain edema and macromolecules through the cortical extracellular space. J Neurosurg. 1992;77(3):387-396.
27. Ito U, Tomita H, Tone O, Shishido T, Hayashi H. Formation and resolution of white matter oedema in various types of brain tumours. Acta Neurochir Suppl (Wien). 1990;51:149-151.
28. Reulen HJ, Graham R, Spatz M, Klatzo I. Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg. 1977;46(1): 24-35.
29. Tengvar C, Olsson Y. Uptake of macromolecules into neurons from a focal vasogenic cerebral edema and subsequent axonal spread to other brain regions. A preliminary study in the mouse with horseradish peroxidase as a tracer. Acta Neuropathol. 1982;57(2-3):233-235.
30. Vorbrodt AW, Lossinsky AS,Wisniewski HM, et al. Ultrastructural observations on the transvascular route of protein removal in vasogenic brain edema. Acta Neuropathol. 1985;66(4):265-273.
31. Wolman M, Klatzo I, Chui E, et al. Evaluation of the dye-protein tracers in pathophysiology of the blood-brain barrier. Acta Neuropathol. 1981;54(1):55-61.
32. Baethmann A, Lanksch W, Schmiedek P. Formation and treatment of cerebral edema. Neurochirurgia. 1974;17(2):37-47.
33. Shapiro WR, Hiesiger EM, Cooney GA, Basler GA, Lipschutz LE, Posner JB. Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma. J Neurooncol. 1990;8(3):197-204.
34. Barnes D, McDonald WI. A magnetic resonance imaging study of experimental cerebral edema and its response to dexamethasone. Magn Reson Med. 1988;7(1):125-131.
35. Ito U, Reulen HJ, Tomita H, Ikeda J, Saito J, Maehara T. A computed tomography study on formation, propagation, and resolution of edema fluid in metastatic brain tumors. Adv Neurol. 1990;52:459-468.
36. Hossmann KA, Hurter T, Oschlies U. The effect of dexamethasone on serum protein extravasation and edema development in experimental brain tumors of cat. Acta Neuropathol. 1983;60(3-4):223-231.
37. Hadjidimos A, Steingass U, Fischer F, Reulen HJ, Schurmann K. The effects of dexamethasone on rCBF and cerebral vasomotor response in brain tumors. Preliminary communication. Eur Neurol. 1973;10(1):25-30.
38. Warnke PC, Molnar P, Lapin GD, Kuruvilla A, Groothuis DR. The effects of dexamethasone on transcapillary transport in experimental brain tumors: II. Canine brain tumors. J Neurooncol. 1995;25(1):29-38.
39. Chumas P, Condon B, Oluoch-Olunya D, Griffiths S, Hadley D, Teasdale G. Early changes in peritumorous oedema and contralateral white matter after dexamethasone: a study using proton magnetic resonance spectroscopy. J Neurol Neurosurg Psychiatry. 1997;62(6):590-595.
40. Molnar P, Lapin GD, Groothuis DR. The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. J Neurooncol. 1995;25(1):19-28.
41. Klatzo I, Chui E, Fujiwara K, Spatz M. Resolution of vasogenic brain edema. Adv Neurol. 1980;28:359-373.
42. Leenders KL, Beaney RP, Brooks DJ, Lammertsma AA, Heather JD, McKenzie CG. Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization. Neurology. 1985;35(11):1610-1616.
43. Wilkinson ID, Jellineck DA, Levy D, et al. Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery. 2006;58(4):640- 646; discussion 640-646.
44. Miller JD, Leech P. Effects of mannitol and steroid therapy on intracranial volume-pressure relationships in patients. J Neurosurg. 1975;42(3):274-281.
45. Langfitt TW. Increased intracranial pressure. Clin Neurosurg. 1969;16:436-471.
46. McEwen BS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci. 1991;12(4):141-147.
47. Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids. 2005;70(5-7):407-417.
48. Yu ZY, Wrange O, Boethius J, Hatam A, Granholm L, Gustafsson JA. A study of glucocorticoid receptors in intracranial tumors. J Neurosurg. 1981;55(5):757-760.
49. Carroll RS, Zhang J, Dashner K, Sar M, Black PM. Steroid hormone receptors in astrocytic neoplasms. Neurosurgery. 1995;37(3):496-503; discussion 503-494.
50. Ellemann K, Christensen L, Gjerris F, Briand P, Kruse-Larsen C. Glucocorticoid receptors in glioblastoma multiforme: a new approach to antineoplastic glucocorticoid therapy. Acta Neurochir (Wien). 1988;93(1-2):6-9.
51. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest. 1996;98(6):1400-1408.
52. Beato M, Chalepakis G, Schauer M, Slater EP. DNA regulatory elements for steroid hormones. J Steroid Biochem. 1989;32(5):737-747.
53. Forster C, Waschke J, Burek M, Leers J, Drenckhahn D. Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J Physiol. 2006;573(Pt 2):413-425.
54. Wolff JE, Guerin C, Laterra J, et al. Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res. 1993;604 (1-2):79-85.
55. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999;13(9):1055-1066.
56. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284(5422):1994-1998.
57. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359(6398):845-848.
58. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005;26(4):777-783.
59. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. Aug 19 1983;221(4612):719-725.
60. Maciunas RJ, Mericle RA, Sneed CL, Hefner DJ, Commers PA, Kovacs WJ. Determination of the lethal dose of dexamethasone for early passage in vitro human glioblastoma cell cultures. Neurosurgery. 1993;33(3):485-488; discussion .488.
61. Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol. 2003;5(4):235-243.
62. Machein MR, Kullmer J, Ronicke V, et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol. 1999;25(2):104-112.
63. Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol. 2008;583(2-3):322-339.
64. Ohnishi T, Posner JB, Shapiro WR. Vasogenic brain edema induced by arachidonic acid: role of extracellular arachidonic acid in blood-brain barrier dysfunction. Neurosurgery. 1992;30(4):545-551.
65. Behrens PF, Ostertag CB, Warnke PC. Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study. Neurosurgery. 1998;43(2):235-240; discussion 240-231.
66. Ohnishi T, Iwasaki H, Hayakawa T, Shapiro WR. Possible mechanism of vasogenic brain oedema induced by arachidonic acid. Acta Neurochir Suppl (Wien). 1990;51:65-67.
67. Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet. 1983;1(8330):904-906.
68. Black KL, Hoff JT. Leukotrienes increase blood-brain barrier permeability following intraparenchymal injections in rats. Ann Neurol. 1985;18(3):349-351.
69. Black KL, Hoff JT,McGillicuddy JE, Gebarski SS. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol. 1986;19(6):592-595.
70. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277(47): 44877-44885.
71. Pickard JD. Role of prostaglandins and arachidonic acid derivatives in the coupling of cerebral blood flow to cerebral metabolism. J Cereb Blood Flow Metab. 1981;1(4):361-384.
72. Constantini S, Tamir J, Gomori MJ, Shohami E. Tumor prostaglandin levels correlate with edema around supratentorial meningiomas. Neurosurgery. 1993;33(2):204-210; discussion 211.
73. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol. 2003;45(3):169-184.
74. Karaarslan E, Arslan A. Diffusion weighted MR imaging in non-infarct lesions of the brain. Eur J Radiol. 2008;65(3):402-416.
75. Yamasaki F, Kurisu K, Satoh K, et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology. 2005;235(3):985-991.
76. Kitis O, Altay H, Calli C, Yunten N, Akalin T, Yurtseven T. Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol. 2005;55(3):393-400.
77. Bode MK, Ruohonen J, Nieminen MT, Pyhtinen J. Potential of diffusion imaging in brain tumors: a review. Acta Radiol. 2006;47(6):585-594.
78. Wintermark M, Sesay M, Barbier E, et al. Comparative overview of brain perfusion imaging techniques. Stroke. 2005;36(9):e83-99.
79. Knutsson L, Borjesson S, Larsson EM, et al. Absolute quantification of cerebral blood flow in normal volunteers: correlation between Xe-133 SPECT and dynamic susceptibility contrast MRI. J Magn Reson Imaging. 2007;26(4):913-920.
80. Dong Q, Welsh RC, Chenevert TL, et al. Clinical applications of diffusion tensor imaging. J Magn Reson Imaging. 2004;19(1):6-18.
81. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology. 2002;223(1):11-29.
82. Hajek M, Dezortova M. Introduction to clinical in vivo MR spectroscopy. Eur J Radiol. 2008;67(2):185-193.
83. Drost DJ, Riddle WR, Clarke GD. Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med Phys. 2002;29(9): 2177-2197.
84. Callot V, Galanaud D, Le Fur Y, Confort-Gouny S, Ranjeva JP, Cozzone PJ. (1)H MR spectroscopy of human brain tumours: a practical approach. Eur J Radiol. 2008;67(2):268-274.
85. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol. 2007;62(2):109-119.
86. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology. 2006;238(3):958-969.
87. Hollingworth W, Medina LS, Lenkinski RE, et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol. 2006;27(7):1404-1411.
88. Hatam A, Bergstrom M, Yu ZY, Granholm L, Berggren BM. Effect of dexamethasone treatment on volume and contrast enhancement of intracranial neoplasms. J Comput Assist Tomogr. 1983;7(2):295-300.
89. Crocker EF, Zimmerman RA, Phelps ME, Kuhl DE. The effect of steroids on the extravascular distribution of radiographic contrast material and technetium pertechnetate in brain tumors as determined by computed tomography. Radiology. 1976;119(2):471-474.
90. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12(9):1886-1889.
91. Forsyth PA, Petrov E, Mahallati H, et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol. 1997;15(5):2076-2081.
92. Jarden JO, Dhawan V, Poltorak A, Posner JB, Rottenberg DA. Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of 82Rb: the effect of dexamethasone and whole-brain radiation therapy. Ann Neurol. 1985;18(6):636-646.
93. Jarden JO. Pathophysiological aspects of malignant brain tumors studied with positron emission tomography. Acta Neurol Scand Suppl. 1994;156:1-35.
94. Tada E, Matsumoto K, Kinoshita K, Furuta T, Ohmoto T. The protective effect of dexamethasone against radiation damage induced by interstitial irradiation in normal monkey brain. Neurosurgery. 1997;41(1):209-217; discussion 217-209.
95. Fross RD, Warnke PC, Groothuis DR. Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research. J Neuro-oncol. 1991;11(3):185-197.
96. Matsuoka S, Arakaki Y, Numaguchi K, Ueno S. The effect of dexamethasone on electroencephalograms in patients with brain tumors with specific reference to topographic computer display of delta activity. J Neurosurg. 1978;48(4):601-608.
97. French LA, Galicich JH. The use of steroids for control of cerebral edema. Clin Neurosurg. 1964;10:212-223.
98. Kullberg G, West KA. Influence of corticosteroids on the ventricular fluid pressure. Acta Neurol Scand Suppl. 1965;13(Pt 2):445-452.
99. Reulen HJ, Hadjidimos A, Schurmann K. The effect of dexamethasone on water and electrolyte content and on rCBF in perifocal brain edema in man. In: Reulen HJ, Schfirmann K, eds. Steroids and Brain Edema. Berlin/Heidelberg/New York: Springer; 1972.
100. Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and bloodbrain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg. 1999;90(2):300-305.
101. Jarden JO, Dhawan V, Moeller JR, Strother SC, Rottenberg DA. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann Neurol. 1989;25(3):239-245.
102. Lu S, Ahn D, Johnson G, Cha S. Peritumoral diffusion tensor imaging of highgrade gliomas and metastatic brain tumors. AJNR Am J Neuroradiol. 2003;24(5): 937-941.
103. Choi YL, Suh YL, Kim D, Ko YH, Sung CO, Lee JI. Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy. Clin Neuropathol. 2006;25(1):29-36.
104. Fatouros PP, Marmarou A, Kraft KA, Inao S, Schwarz FP. In vivo brain water determination by T1 measurements: effect of total water content, hydration fraction, and field strength. Magn Reson Med. 1991;17(2):402-413.
105. Kamman RL, Go KG, Brouwer W, Berendsen HJ. Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, protein concentration, and temperature. Magn Reson Med. 1988;6(3):265-274.
106. Fu Y, Tanaka K, Nishimura S. Evaluation of brain edema using magnetic resonance proton relaxation times. Adv Neurol. 1990;52:165-176.
107. Andersen C, Haselgrove JC, Doenstrup S, Astrup J, Gyldensted C. Resorption of peritumoural oedema in cerebral gliomas during dexamethasone treatment evaluated by NMR relaxation time imaging. Acta Neurochir (Wien). 1993;122 (3-4):218-224.
108. Andersen C, Astrup J, Gyldensted C. Quantitative MR analysis of glucocorticoid effects on peritumoral edema associated with intracranial meningiomas and metastases. J Comput Assist Tomogr. 1994;18(4):509-518.
109. Andersen C, Astrup J, Gyldensted C. Quantitation of peritumoural oedema and the effect of steroids using NMR-relaxation time imaging and blood-brain barrier analysis. Acta Neurochir Suppl (Wien). 1994;60:413-415.
110. Andersen C. The effect of glucocorticoids in the normal cerebral hemisphere of brain tumour patients. Acta Neurol Scand. 1998;98(6):433-438.
111. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol. 2009;64(1):12-21.
112. DeLaPaz RL, Patronas NJ, Brooks RA, et al. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. AJNR Am J Neuroradiol. 1983;4(3):826-829.
113. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol. 1992;12(2):159-165.
114. Roelcke U, Blasberg RG, von Ammon K, et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med. 1998;39(5):879-884.
115. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg. 1995;83(4):657-664.
116. Reivich M, Alavi A, Wolf A, et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab. 1985;5(2):179-192.
117. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28(5): 897-916.
118. Olgemoller B, Schon J, Wieland OH. Endothelial plasma membrane is a glucocorticoid- regulated barrier for the uptake of glucose into the cell. Mol Cell Endocrinol. 1985;43(2-3):165-171.
119. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol. 1992;54:911-930.
120. McEwen BS, De Kloet ER, Rostene W. Adrenal steroid receptors and actions in the nervous system. Physiol Rev. 1986;66(4):1121-1188.
121. Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol. 2006;27(2):402-408.
122. Van Roost D, Hartmann A, Quade G. Changes of cerebral blood flow following dexamethasone treatment in brain tumour patients. A Xe/CT study. Acta Neurochir (Wien). 2001;143(1):37-43; discussion 43-34.
123. Minamikawa S, Kono K, Nakayama K, et al. Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology. 2004;46(10):805-811.
124. Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry. 2004;75(11):1632-1635.
125. Sinha S, Bastin ME, Whittle IR, Wardlaw JM. Diffusion tensor MR imaging of high-grade cerebral gliomas. AJNR Am J Neuroradiol. 2002;23(4):520-527.
126. Bastin ME, Sinha S, Whittle IR, Wardlaw JM. Measurements of water diffusion and T1 values in peritumoural oedematous brain. Neuroreport. 2002;13(10):1335-1340.
127. Bastin ME, Delgado M, Whittle IR, Cannon J, Wardlaw JM. The use of diffusion tensor imaging in quantifying the effect of dexamethasone on brain tumours. Neuroreport. 1999;10(7):1385-1391.
128. Sinha S, Bastin ME, Whittle IR. Rapid clinical deterioration in a patient with multi-focal glioma despite corticosteroid therapy: a quantitative MRI study. Br J Neurosurg. 2003;17(6):537-540; discussion 540.
129. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17(2):357-367.
130. Armitage PA, Schwindack C, Bastin ME, Whittle IR. Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn Reson Imaging. 2007;25(3):303-310.
131. Bodsch W, Rommel T, Ophoff BG, Menzel J. Factors responsible for the retention of fluid in human tumor edema and the effect of dexamethasone. J Neurosurg. 1987;67(2):250-257.
132. Huisman TA, Sorensen AG. Perfusion-weighted magnetic resonance imaging of the brain: techniques and application in children. Eur Radiol. 2004;14(1):59-72.
133. Hakyemez B, Erdogan C, Ercan I, Ergin N, Uysal S, Atahan S. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol. 2005;60(4):493-502.
134. Jeswani T, Padhani AR. Imaging tumour angiogenesis. Cancer Imaging. 2005;5:131-138.
135. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst. 1972;48(2):347-356.
136. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992;340(8812):145-146.
137. Quarles CC, Krouwer HG, Rand SD, Schmainda KM. Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters. Technol Cancer Res Treat. 2005;4(3):245-249.
138. Andersen C, Jensen FT. Differences in blood-tumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment. Acta Neurochir (Wien). 1998;140(9):919-924.
139. Hatam A, Yu ZY, Bergstrom M, Berggren BM, Greitz T. Effect of dexamethasone treatment on peritumoral brain edema: evaluation by computed tomography. J Comput Assist Tomogr. 1982;6(3):586-592.
140. Namba H, Togawa T, Yui N, et al. The effect of steroid on thallium-201 uptake by malignant gliomas. Eur J Nucl Med. 1996;23(8):991-992.
141. Ludemann L, Warmuth C, Plotkin M, et al. Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H2 (15)O positron emission tomography. Eur J Radiol. 2009;70(3):465-474.
142. Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol. 2000;175(1):207-219.
143. Jackson A, Kassner A, Zhu XP, Li KL. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging. 2001;14(5):510-516.
144. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magn Reson Med. 1996;36(5):726-736.
145. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis. Magn Reson Med. 1996;36(5):715-725.
146. Calamante F, Gadian DG, Connelly A. Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Magn Reson Med. 2000;44(3):466-473.
147. Calamante F, Gadian DG, Connelly A. Quantification of perfusion using bolus tracking magnetic resonance imaging in stroke: assumptions, limitations, and potential implications for clinical use. Stroke. 2002;33(4):1146-1151.
148. Hawighorst H, Libicher M, Knopp MV, Moehler T, Kauffmann GW, Kaick G. Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging. 1999;10(3):286-294.
149. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrastenhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed. 2002;15(2):132-142.
150. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7(1):91-101.
151. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223-232.
152. Jackson A, Jayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrastenhanced MRI in newly presenting glioma. Br J Radiol. 2003;76(903):153-162.
153. Li KL, Zhu XP, Jayson G, et al. Quantitative dynamic contrast-enhanced MRI in tumors. A reproducible technique in the head A reproducible technique in the breast Proc Intl Sot Magn Reson Med. 2000;8:724.
154. Carroll TJ, Teneggi V, Jobin M, et al. Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab. 2002;22(9):1149-1156.
155. Ostergaard L, Johannsen P, Host-Poulsen P, et al. Cerebral blood flow measurements by magnetic resonance imaging bolus tracking: comparison with [(15)O]H2O positron emission tomography in humans. J Cereb Blood Flow Metab. 1998;18(9):935-940.
156. Grandin CB, Bol A, Smith AM, Michel C, Cosnard G. Absolute CBF and CBV measurements by MRI bolus tracking before and after acetazolamide challenge: repeatability and comparison with PET in humans. Neuroimage. 2005;26(2):525-535.
157. Mukherjee P, Kang HC, Videen TO, McKinstry RC, Powers WJ, Derdeyn CP. Measurement of cerebral blood flow in chronic carotid occlusive disease: comparison of dynamic susceptibility contrast perfusion MR imaging with positron emission tomography. AJNR Am J Neuroradiol. 2003;24(5):862-871.
158. Mihara F, Kuwabara Y, Yoshiura T, et al. Semi-quantitative CBF and CBF ratios obtained using perfusion-weightedMR imaging. Neuroreport. 2003;14(5):725-727.
159. Hagen T, Bartylla K, Piepgras U. Correlation of regional cerebral blood flow measured by stable xenon CT and perfusion MRI. J Comput Assist Tomogr. 1999;23(2):257-264.
160. MacDonald HL, Bell BA, Smith MA, et al. Correlation of human NMR T1 values measured in vivo and brain water content. Br J Radiol. 1986;59(700): 355-357.
161. Andersen C, Jensen FT. Precision, accuracy, and image plane uniformity in NMR relaxation time imaging on a 1.5 T whole-body MR imaging system. Magn Reson Imaging. 1994;12(5):775-784.
162. Basser PJ, Jones DK. Diffusion-tensor MRI: theory, experimental design and data analysis-a technical review. NMR Biomed. 2002;15(7-8):456-467.
163. Bonekamp D, Nagae LM, Degaonkar M, et al. Diffusion tensor imaging in children and adolescents: reproducibility, hemispheric, and age-related differences. Neuroimage. 2007;34(2):733-742.
164. Muller MJ, Mazanek M, Weibrich C, Dellani PR, Stoeter P, Fellgiebel A. Distribution characteristics, reproducibility, and precision of region of interestbased hippocampal diffusion tensor imaging measures. AJNR Am J Neuroradiol. 2006;27(2):440-446.
165. Heim S, Hahn K, Samann PG, Fahrmeir L, Auer DP. Assessing DTI data quality using bootstrap analysis. Magn Reson Med. 2004;52(3):582-589.
166. Jansen JF, Kooi ME, Kessels AG, Nicolay K, Backes WH. Reproducibility of quantitative cerebral T2 relaxometry, diffusion tensor imaging, and 1H magnetic resonance spectroscopy at 3.0 Tesla. Invest Radiol. 2007;42(6):327-337.
167. Landman BA, Farrell JA, Jones CK, Smith SA, Prince JL, Mori S. Effects of diffusion weighting schemes on the reproducibility of DTI-derived fractional anisotropy, mean diffusivity, and principal eigenvector measurements at 1.5T. Neuroimage. 2007;36(4):1123-1138.
168. Marshall I,Wardlaw J, Cannon J, Slattery J, Sellar RJ. Reproducibility of metabolite peak areas in 1H MRS of brain. Magn Reson Imaging. 1996;14(3):281-292.
169. Tedeschi G, Bertolino A, Campbell G, et al. Reproducibility of proton MR spectroscopic imaging findings. AJNR Am J Neuroradiol. 1996;17(10): 1871-1879.
170. Binesh N, Yue K, Fairbanks L, Thomas MA. Reproducibility of localized 2D correlated MR spectroscopy. Magn Reson Med. 2002;48(6):942-948.
171. Chard DT, McLean MA, Parker GJ, MacManus DG, Miller DH. Reproducibility of in vivo metabolite quantification with proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging. 2002;15(2):219-225.